Background Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a
potential alternative to allopurinol for patients with hyperuricemia and gout. Methods We …

Objective To compare the urate‐lowering efficacy and safety of febuxostat, allopurinol, and
placebo in a large group of subjects with hyperuricemia and gout, including persons with …

Objective Gout affects ∼1–2% of the American population. Current options for treating
hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and …

Objective. To determine longterm urate-lowering efficacy and clinical benefits and safety of
therapy with febuxostat or allopurinol in subjects with gout. Methods. Subjects (n = 1086) in …

Purpose: Although the murine orthologue of glycoprotein nonmetastatic B (GPNMB),
Osteoactivin, promotes breast cancer metastasis in an in vivo mouse model, its importance in …

BACKGROUND: Use of urate-lowering therapy (ULT), such as febuxostat or allopurinol, is
recommended for the long-term management of hyperuricemia in patients with gout to reduce …

Background: The association between hyperuricemia, gout, and impaired renal function has
long been recognized. Recent data provide evidence for the causal relationship between …

Clinical benefit early in urate-lowering treatment of gout is difficult to document. We examined
data from 1,832 gouty subjects treated with either urate-lowering agents or placebo to …

Objective To assess the effect of treatment with febuxostat versus placebo on joint damage
in hyperuricemic subjects with early gout (1 or 2 gout flares). Methods In this double‐blind, …

Objective. To summarize the endorsement of measures of patient-reported outcome (PRO)
domains in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (…